

AMRYT PHARMA PLC

Form of Proxy

2022 Annual General Meeting (the “AGM”) of
Amryt Pharma plc (the “Company”)
to be held at the Company’s headquarters at 45 Mespil Road, Dublin 4, Ireland
at 2:00 p.m. BST (9:00 a.m. EST) on June 30, 2022

The Company’s 2022 AGM will be held at its headquarters in Dublin, Ireland at 2:00 p.m. BST (9:00 a.m. EST) on June 30, 2022. The health and welfare of our Shareholders and colleagues is our priority in making arrangements for the AGM. Therefore, in planning the AGM, we have been mindful above all of the need to ensure a COVID-secure meeting with appropriate social distancing for any Shareholders who might wish, subject to the UK and Irish Governments’ ongoing guidance on public gatherings relating to the COVID-19 pandemic, to attend the AGM in person. The Company continues to closely monitor the situation in respect of COVID-19.

The AGM will take place at the time, date and venue stated above. **Shareholders are strongly encouraged to vote in advance of the AGM by lodging a completed Form of Proxy or submitting an electronic filing via the share portal service or a proxy instruction via the CREST proxy voting service and appointing the Chairman of the AGM as their proxy. This means that the Chairman of the AGM will be able to vote on their behalf, and in accordance with their instructions, at the AGM.**

We will continue to monitor developments, including the latest UK and Irish Governments’ measures relating to COVID-19, and in the event that the AGM arrangements change, the Company will issue an announcement via our website at <https://amrytpharma.com/newsroom/>. If you are experiencing any of the symptoms connected with COVID-19 or are a close contact of someone with COVID-19, we would ask that you please do not attend the AGM.

To support engagement with our Shareholders, the Company intends to provide a telephone facility to allow Shareholders to listen to the formal business of the AGM. Any such Shareholder participation via the telephone facility will not constitute formal attendance at the AGM, and Shareholders will not be able to vote on any resolutions via the telephone facility.

The dial-in numbers for Shareholders (or their duly appointed proxies or corporate representatives) to access the telephone facility are as follows: Ireland: +353 (0) 1 506 0650; UK: +44 (0) 844 481 9752 and US: +1 646 741 3167 (Passcode: 8966839). Please note that if you appoint any person other than the Chairman of the AGM as your proxy, that person will need to attend the AGM in person to cast your vote as directed. Such person will not be deemed to have attended the AGM in person by dialling into the telephone facility.

The Company also encourages Shareholders to submit questions to, or raise matters of concern in relation to the formal business of the AGM with, the Board by email to ir@amrytpharma.com, to arrive by no later than 2:00 p.m. BST (9:00 a.m. EST) on June 27, 2022. Please include your full name and contact details. The Company will endeavour to answer any questions received by Shareholders by the time specified above during the AGM.

Unless otherwise defined herein, capitalised terms in this Form of Proxy shall have the meanings given to them in the notice of AGM of the Company dated and published on June 1, 2022 (the “Notice of AGM”).

If you hold your shares in certificated form, you may appoint a proxy by completing this Form of Proxy or by submitting your proxy electronically at www.signalsshare.com (please refer to note 16).

The Board strongly encourages Shareholders to appoint the Chairman of the AGM as their proxy to cast their votes as directed.

I/We

being a member/members of the Company, hereby appoint the Chairman of the AGM or (see note 5)

Full name of proxy

as my/our proxy to attend and vote on my/our behalf at the annual general meeting of the Company to be held at the Company's headquarters at 45 Mespil Road, Dublin 4, Ireland at 2:00 p.m. BST (9:00 a.m. EST) on June 30, 2022 and at any adjournment thereof.

I/We instruct my/our appointed proxy to vote as indicated below in respect of the Resolutions which are referred to on pages 7 to 8 of the Notice of AGM.

Please tick here if you are appointing more than one proxy (see note 6).

Number of Ordinary Shares proxy appointed over (see note 6).

Please mark "X" to indicate how you wish to vote.

RESOLUTIONS	FOR	AGAINST	VOTE WITHHELD
ORDINARY RESOLUTIONS			
1. To receive and adopt the financial statements of the Company for the year ended December 31, 2021, together with the reports of the Directors and auditor thereon (the "2021 Annual Report").	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. To approve the Directors' remuneration report, as set out in the 2021 Annual Report.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. To re-appoint Mr. Rajkumar Kannan as a Director of the Company, who is retiring in accordance with articles 89.2 and 117 of the Company's articles of association and, being eligible, is offering himself for re-appointment.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. To re-appoint Dr. Roni Mamluk as a Director of the Company, who is retiring in accordance with articles 89.2 and 117 of the Company's articles of association and, being eligible, is offering herself for re-appointment.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. To re-appoint Dr. Alain Munoz as a Director of the Company, who is retiring in accordance with article 117 of the Company's articles of association and, being eligible, is offering himself for re-appointment.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. To re-appoint Grant Thornton as auditor of the Company to hold office from the conclusion of this meeting until the conclusion of the next annual general meeting at which accounts are laid before the Company and to authorise the Audit Committee to determine their remuneration.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. THAT the Directors be generally and unconditionally authorised in accordance with section 551 of the Companies Act, to exercise all the powers of the Company to allot shares and grant rights to subscribe for, or to convert any security into, shares:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

(a) up to an aggregate nominal amount of £6,417,696 (such amount to be reduced by the nominal amount allotted or granted under paragraph (b) of this resolution 7 in excess of such sum); and

(b) comprising equity securities (as defined in section 560 of the

Companies Act) up to an aggregate nominal amount of £12,835,393 (such amount to be reduced by any allotment or grant made under paragraph (a) of this resolution 7) in connection with or pursuant to an offer by way of a rights issue in favour of holders of Ordinary Shares in proportion (as nearly as practicable) to the respective number of Ordinary Shares held by them on the record date for such allotment (and holders of any other class of equity securities entitled to participate therein or, if the Directors consider it necessary, as permitted by the rights of those securities), but subject to such exclusions or other arrangements as the Directors may consider necessary or appropriate to deal with fractional entitlements, treasury shares, record dates or legal, regulatory or practical difficulties which may arise under the laws of, or the requirements of any regulatory body or stock exchange in, any territory or by virtue of shares being represented by depositary receipts or any other matter whatsoever,

and these and these authorisations shall be in addition to all other authorities under section 551 of the Companies Act and shall expire at the conclusion of the annual general meeting of the Company held in 2023 or, if earlier, at 6.00 p.m. on September 30, 2023, save that the Company may before such expiry make any offer or agreement which would or might require shares to be allotted, or rights to be granted, after such expiry and the Directors may allot shares, or grant rights to subscribe for or to convert any security into shares, in pursuance of any such offer or agreement as if the authorisations conferred hereby had not expired.

SPECIAL RESOLUTION

8. THAT, subject to and conditional upon the passing of resolution 7, the Directors be given power pursuant to sections 570 and 573 of the Companies Act to:

(a) allot equity securities (within the meaning of section 560 of the Companies Act) for cash pursuant to the authorisation conferred by resolution 7; and

(b) sell ordinary shares (within the meaning of section 560 of the Companies Act) held by the Company as treasury shares for cash,

as if section 561(1) of the Companies Act did not apply to any such allotment or sale, provided that this power shall be limited to the allotment of equity securities for cash and the sale of treasury shares:

(i) in connection with or pursuant to an offer of or invitation to acquire equity securities (but in the case of the authorisation granted under paragraph (b) of resolution 7, by way of a rights issue only) in favour of holders of Ordinary Shares in proportion (as nearly as practicable) to the respective number of Ordinary Shares held by them on the record date for such allotment or sale (and holders of any other class of equity securities entitled to participate therein or, if the Directors consider it necessary, as permitted by the rights of those securities) but subject to such exclusions or other arrangements as the Directors may consider necessary or appropriate to deal with fractional entitlements, treasury shares, record dates or legal, regulatory or practical difficulties which may arise under the laws of, or the requirements of any regulatory body or stock exchange in, any territory or by virtue of shares being represented by depositary receipts or any other matter whatsoever; and

(ii) in the case of the authorisation granted under paragraph (a) of resolution 7 (or in the case of any transfer of treasury shares), and

otherwise than pursuant to paragraph i. of this resolution 8, up to an aggregate nominal amount of £3,850,618,

and these authorisations shall be in addition to all other authorities under sections 570 and 573 of the Companies Act and shall expire at the conclusion of the annual general meeting of the Company held in 2023 or, if earlier, at 6.00 p.m. on September 30, 2023, save that the Company may before such expiry make any offer or agreement that would or might require equity securities to be allotted, or treasury shares to be sold, after such expiry and the Directors may allot equity securities, or sell treasury shares in pursuance of any such offer or agreement as if the power conferred hereby had not expired.

Signature or
execution:

Date:

Notes

- The Company continues to monitor the situation in respect of COVID-19. The health and welfare of our Shareholders and colleagues is our priority in making arrangements for the AGM. Therefore, in planning the AGM, we have been mindful above all of the need to ensure a COVID-secure meeting with appropriate social distancing for any Shareholders who might wish, subject to UK and Irish Governments' ongoing guidance on public gatherings relating to the COVID-19 pandemic, to attend the AGM in person. Shareholders are strongly encouraged to vote in advance of the AGM by lodging a completed Form of Proxy or submitting an electronic filing via the share portal service or a proxy instruction via the CREST proxy voting service and appointing the Chairman of the AGM as their proxy to cast their votes as directed.**
- To support engagement with Shareholders, the Company intends to provide a telephone facility to allow Shareholders to listen to the formal business of the AGM. Any such Shareholder participation via the telephone facility will not constitute formal attendance at the AGM, and Shareholders will not be able to vote on any resolutions via the telephone facility. The dial-in numbers for Shareholders (or their duly appointed proxies or corporate representatives) to access the telephone facility are as follows: Ireland: +353 (0) 1 506 0626; UK: +44 (0) 203 009 5709 and US: +1 646 787 1226 (Passcode: 4345819). Please note that if you appoint any person other than the Chairman of the AGM as your proxy, that person will need to attend the AGM in person to cast your vote as directed. Such person will not be deemed to have attended the AGM in person by dialling into the telephone facility. The Company also encourages Shareholders to submit questions to, or raise matters of concern in relation to the formal business of the AGM with, the Board by email to ir@amrytpharma.com, to arrive by no later than 2:00 p.m. BST (9:00 a.m. EST) on June 27, 2022. Please include your full name and contact details. The Company will endeavour to answer any questions received by Shareholders by the time specified above during the AGM. The Board will keep the situation under review and may need to make changes to the arrangements relating to the AGM, including how it is conducted, and Shareholders should therefore continue to monitor the Company's website for any update.
- To be entitled to attend and vote at the AGM (or any adjournment thereof) (and for the purpose of the determination by the Company of the number of votes that can be cast thereat), Shareholders must be registered in the register of members of the Company as at 6:00 p.m. on June 28, 2022 (or, in the case of any adjournment of the AGM, no later than 48 hours (excluding any part of a day that is not a Business Day) before the time appointed for the holding of the adjourned AGM). Changes to the register of members of the Company after the relevant deadline shall be disregarded in determining the rights of any person to attend and vote at the AGM (or any adjournment thereof). **However, as set out in note 1, the Board strongly encourages Shareholders to vote on all resolutions being proposed at the AGM by lodging a completed Form of Proxy or submitting an electronic filing via the share portal service or a proxy instruction via the CREST proxy voting service and appointing the Chairman of the AGM as their proxy to cast their votes as directed.**
- Shareholders, or their proxies, entitled to attend the AGM (or any adjournment thereof) in person are requested, if possible, to arrive at the venue at least 20 minutes prior to the commencement of the AGM at 2:00 p.m. BST (9:00 a.m. EST) on June 30, 2022 (or, in the case of any adjournment of the AGM, the relevant time and date of the adjourned AGM) so that their shareholding may be checked against the Company's register of members and attendances recorded. If you are experiencing any of the symptoms connected with COVID-19 or are a close contact of someone with COVID-19, we would ask that you please do not attend the AGM.
- A Shareholder who is entitled to attend and vote at the AGM (or any adjournment thereof) is entitled to appoint another person or persons as its proxy or proxies to exercise all or any of the Shareholder's rights to attend and vote at the AGM (or any adjournment thereof). If a Shareholder wishes to appoint more than one proxy, each proxy must be appointed to exercise the rights attached to a different Ordinary Share or Ordinary Shares held by the Shareholder. A proxy need not be a member of the Company but must attend the AGM (and any adjournment thereof). You can (and are strongly encouraged by the Board to) appoint the Chairman of the AGM as your proxy. If you wish to appoint someone other than the Chairman of the AGM, insert the full name of your appointee in the appropriate box. If you sign and return this Form of Proxy with no name inserted in the box, the Chairman of the AGM will be deemed to be your proxy.

6. If you wish to appoint more than one proxy, you may: (a) photocopy this Form of Proxy, fill in the name of the proxy and the number of Ordinary Shares in respect of which the proxy is appointed and send the multiple forms together to Link Group at the address in note 11; or (b) call or email Link Group on the number in note 22 who will then issue you with multiple Forms of Proxy. Please also indicate by ticking the box provided if the proxy instruction is one of multiple instructions being given. Please ensure that for each proxy appointed in this way, you fill in, in the box provided, the number of Ordinary Shares in respect of which each proxy is appointed. If you are appointing a proxy in relation to less than your full voting entitlement, please enter in the box provided the number of Ordinary Shares in relation to which they are authorised to act as your proxy. If left blank your proxy will be deemed to be authorised in respect of your full voting entitlement (or if the Form of Proxy has been issued in respect of a designated account for a Shareholder, the full voting entitlement for that designated account). All Forms of Proxy must be signed and should be returned together in a single envelope, rather than posted separately, if possible.
7. To direct your proxy how to vote on the resolutions being proposed at the AGM mark the appropriate box with an 'X'. If no voting indication is given, your proxy will vote, or abstain from voting, at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the AGM. The 'vote withheld' option is to enable you to abstain on any of the resolutions. However, it should be noted that a vote withheld is not a vote in law and will not be counted in the proportion of votes 'for' and 'against' the relevant resolution.
8. In the case of joint Shareholders, only one need sign the Form of Proxy. The vote of the senior joint Shareholder will be accepted to the exclusion of the votes of the other joint Shareholders. For this purpose, seniority will be determined by the order in which the names of the Shareholders appear in the register of members of the Company in respect of the joint shareholding.
9. A corporation should execute the Form of Proxy under its common seal or otherwise in accordance with section 44 of the Companies Act or by signature on its behalf by a duly authorised officer or attorney whose power of attorney or other authority should be enclosed with the Form of Proxy.
10. Any power of attorney or any other authority under which the Form of Proxy is signed (or a duly certified, or notarially authenticated copy if executed outside the UK, copy of such power or authority) must be included with the Form of Proxy.
11. On completing the Form of Proxy, sign and return it (together with any other Form of Proxy completed and signed by you (please refer to note 6)) to Link Group using the pre-paid envelope provided for use in the UK. If sending from outside the UK, the correct postage will need to be applied. You may, if you prefer, return this Form of Proxy in a sealed stamped envelope to the address referred to below in this note 11. To be valid, the Form of Proxy, together with any power of attorney or other authority under which the Form of Proxy is signed (or a duly certified, or notarially authenticated copy if executed outside the UK, copy of such power or authority) must be received at the offices of PXS 1, Link Group, Central Square, 29 Wellington Street, Leeds, LS1 4DL, United Kingdom by no later than 2:00 p.m. BST (9:00 a.m. EST) on June 28, 2022 (or, in the case of any adjournment of the AGM, no later than 48 hours (excluding any part of a day that is not a Business Day) before the time appointed for the holding of the adjourned AGM). Please return this Form of Proxy by hand or by post (during normal business hours) to PXS 1, Link Group, Central Square, 29 Wellington Street, Leeds, LS1 4DL, United Kingdom.
12. Shareholders who hold through CREST and who wish to appoint a proxy through the CREST proxy voting service for the AGM (or any adjournment thereof) may do so by using the procedures described in the CREST Manual (available at www.euroclear.com). If you hold your Ordinary Shares in CREST and you wish to appoint a proxy or proxies through the CREST electronic proxy appointment service, details of how to do so are set out on pages 10 to 11 of the Notice of AGM.
13. In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a "CREST Proxy Instruction") must be properly authenticated in accordance with Euroclear's specifications and must contain the information required for such instruction, as described in the CREST Manual. The message, regardless of whether it constitutes the appointment of a proxy or an amendment to the instruction given to a previously appointed proxy, must, in order to be valid, be transmitted so as to be received by the issuer's agent (ID: RA10) by the latest time for receipt of proxy appointments specified below. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time, any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.
14. CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider, to procure that his CREST sponsor or voting service provider takes) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001 (SI 2001/3755).
15. If you submit your proxy electronically through CREST, to be valid, the appropriate CREST messages relating to the appointment of a proxy or an instruction to a previously appointed proxy, which are to be transmitted through CREST, must be transmitted so as to be received by the issuer's agent (ID RA10) by no later than 2:00 p.m. BST (9:00 a.m. EST) on June 28, 2022 (or, in the case of any adjournment of the AGM, no later than 48 hours (excluding any part of a day that is not a Business Day) before the time appointed for the holding of the adjourned AGM).
16. Alternatively, you can submit your proxy vote via the internet through the share portal service at www.signalshares.com. To do so, you will need to log on to your share portal account or register for the share portal if you have not already done so. To register for the share portal you will need your investor code. Once registered, you will immediately be able to vote. For an electronic proxy appointment to be valid, the appointment must be received no later than 2:00 p.m. BST (9:00 a.m. EST) on June 28, 2022 (or, in the case of any adjournment of the AGM, no later than 48 hours (excluding any part of a day

- that is not a Business Day) before the time appointed for the holding of the adjourned AGM). If you want to appoint more than one proxy electronically then please contact the Company's registrar using the contact details at note 22.
17. The return of a completed Form of Proxy or the submission of an electronic filing via the share portal service or a proxy instruction via the CREST proxy voting service (as described above) will not prevent a Shareholder from attending the AGM (or any adjournment thereof) and voting in person if he/she wishes to do so.
 18. A Shareholder may change a proxy instruction but to do so you will need to contact the Company's registrar, Link Group. The revocation notice must be received by Link Group by no later than 2:00 p.m. BST (9:00 a.m. EST) on June 28, 2022 (or, in the case of any adjournment of the AGM, no later than 48 hours (excluding any part of a day that is not a Business Day) before the time appointed for the holding of the adjourned AGM). If you attempt to revoke your proxy appointment but the revocation is received after the time specified, your original proxy appointment will remain valid unless you attend the AGM (or any adjournment thereof) and vote in person.
 19. If two or more valid but different instruments of proxy are delivered in respect of the same Ordinary Share for use at the AGM (or any adjournment thereof) the one which is last validly deposited or received shall be treated as replacing and revoking the other Form of Proxy as regards that Ordinary Share. Which proxy is later will be determined on the basis of which proxy is last sent (or, if the Company is unable to determine which is last sent, last received). Proxies in the same envelope will be treated as sent and received at the same time, to minimise the number of conflicting proxies. If conflicting proxies are sent or received at the same time or if the Company is unable to determine which was sent or received last in respect of (or deemed to be in respect of) an entire holding, none of them shall be treated as valid.
 20. Shareholders satisfying the thresholds in section 527 of the Companies Act can require the Company to publish a statement on its website setting out any matter relating to (a) the audit of the Company's accounts (including the auditor's report and the conduct of the audit) that are to be laid before the AGM; or (b) any circumstances connected with an auditor of the Company ceasing to hold office since the last AGM, that the Shareholders propose to raise at the AGM. The Company cannot require the Shareholders requesting the publication to pay its expenses. Any statement placed on the website must also be sent to the Company's auditors no later than the time it makes its statement available on the website. The business which may be dealt with at the AGM includes any such statement that the Company has been required to publish on its website.
 21. You may not use any electronic address (within the meaning of section 333(4) of the Companies Act) provided in this Form of Proxy or any related documents (including the Notice of AGM) to communicate with the Company for any purposes other than those expressly stated.
 22. If you have any questions relating to the completion and/or return of this Form of Proxy, please contact the Company's registrar, Link Group, on +44 (0)371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. The helpline is open between 9.00 a.m. and 5.30 p.m. (BST), Monday to Friday excluding public holidays in England and Wales. Different charges may apply to calls from mobile telephones and calls may be recorded and randomly monitored for security and training purposes. Alternatively, you may submit a request in writing to Link Group by post to PXS 1, Link Group, Central Square, 29 Wellington Street, Leeds, LS1 4DL, United Kingdom or by email to shareholderenquiries@linkgroup.co.uk. Please note that Link Group cannot provide advice on the merits of the proposals referred to in the Notice of AGM or give any financial, legal or tax advice.
 23. The Company may process personal data of attendees and participants at the AGM. This may include webcasts, photos, recording and audio and video links, as well as other forms of personal data. The Company shall process such personal data in accordance with its privacy policy, which can be found at www.amrytpharma.com
 24. Please note that the Company takes all reasonable precautions to ensure no viruses are present in any electronic communication it sends out but the Company cannot accept responsibility for loss or damage arising from the opening or use of any email or attachments from the Company and recommends that Shareholders subject all messages to virus checking procedures prior to use. Any electronic communication received by the Company, including any electronic filing, that is found to contain any virus will not be accepted.
 25. Unless otherwise defined herein, capitalised terms in this Form of Proxy shall have the meanings given to them in the Notice of AGM.